Table 2: Guideline Recommendations Regarding Anticoagulation of Patients with Hypertrophic Cardiomyopathy and Atrial Fibrillation.

Guideline	Issuing body	Year	Patients requiring anticoagulation	Anticoagulation agent (1st line)	Strength of recommendation
ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy[5]	ESC	2014	All patients with HCM and AF	VKA	Class I
ESC guidelines for the management of AF[9]	ESC	2016	All patients with HCM and AF	No preference between vka and noac for hcm	Class I
Guidelines for the diagnosis and treatment of HCM[74]	ACC/AHA	2011	All patients with HCM and AF	VKA	Class I
AHA/ACC/HRS guidelines for the management of patients with AF[75]	AHA/ACC/HRS	2014	All patients with HCM and AF	No specification of VKA or NOAC	Class I
Guidelines for diagnosis and treatment of patients with HCM[59]	JCS	2012	All patients with HCM and AF	No specification of VKA or NOAC	Not stated
Guidelines for the pharmacotherapy of AF[60]	JCS	2013	All patients with HCM and AF	No specification of VKA or NOAC	Class IIa

ACC = American College of Cardiology; AHA = American Heart Association; ESC = European Society of Cardiology; HCM, hypertrophic cardiomyopathy; HRS = Heart Rhythm Society; JCS = Japanese Circulation Society; NOAC = non-vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist.